Total number of patients included in the study were 38, 26 in the low dose group and 12 in the high dose group. In the low dose group, 20 were males and six were females, in the high dose group eight were males and four were females. The commonest underlying diseases were tuberculosis (17 in low dose group, nine in high dose group), Pneumocystis carinii (jeroveci) pneumonia (16 in low dose group, seven in high dose group) and oral candidiasis (eight in low dose group, seven in high dose group), Toxoplasmosis (three in low dose group, one in high dose group), hypertension (1 in group A) and diabetes mellitus (1 in group B).
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meningitis. [1] Cryptococcal meningitis (CM) is still the most common manifestation of systemic fungal infection in human immunodefi ciency virus (HIV) infected patients and remains associated with signifi cant morbidity and mortality. [2] Common presenting symptoms are severe headache; fever, progressive malaise, nausea with vomiting, fatigue, blurred vision and / or sensitivity to bright light, stiff neck, altered behavior changes, coma. [3] The overall incidence of cryptococcal meningitis in patients with AIDS appears to be 5-10%. [4] Recent data indicates that incidence of C.neofomans is high in developing countries. [5] Cryptococcal meningitis has been reported as the most common opportunistic infection of the CNS of Indian patients with HIV. [6] Untreated CM is fatal with very rare exception. [7] For more than 40 years, conventional amphotericin B deoxycholate (AMB) has been considered to be the gold standard for initial treatment of CM in patients with HIV infection, [2] because of its broad fungicidal activity and cheapness. Treatment with AMB however is associated with acute reactions related to infusion and dose dependent nephrotoxicity. [8] 
Objective
To compare the safety and effi cacy of low dose versus high dose of amphotericin B in cryptococcal meningitis associated with HIV infection.
Materials and Methods
A retrospective chart review of patients hospitalized with clinical diagnosis, with or without microbiological evidence of cryptococcal meningitis was collected from Jan 2000-March 2006. Cerebrospinal fl uid (CSF) was studied in these patients. Laboratory investigation of CSF was traditionally based on microscopic examination of Gram's staining, culture and India ink preparations. Patients' details were collected in a patient proforma including patient's age, weight, signs and symptoms of disease and microbiological report (Blood and CSF). Data also included other comorbidities and concomitant medications taken along with AMB. Adverse drug reactions which occurred during the period of AMB treatment were recorded.
Patients were grouped into two groups: low dose group and high dose group, depending on the dose of AMB given for the treatment of CM. Patients who received AMB at doses of 0.33 to 0.64 mg/kg/day were categorized under low dose group and patients who received AMB 0.7 to 1.1 mg/kg/day [9] [10] [11] were categorized under high dose group. All the data were pooled and analyzed between the groups using Chi square test.
Result
Total numbers of subjects included in the study were 38 patients. Among these 26 were in low dose group and 12 were in high dose group. There was a male preponderance in this study.
The demographic data of patients are as shown in the Table 1 .
Typical presentations of CM in these patients were as shown in the Table 2 .The most common signs and symptoms were headache, fever, nausea/vomiting, neck stiffness, cough and behavioral changes etc.
CM was associated with tuberculosis (TB) (26/38 cases), Pneumocystis carinii pneumonia (jeroveci) (23/38 cases) oral candidiasis (OC) (15/38 cases), toxoplasmosis (TXG) (4/38 case), hypertension (HTN) (1/36 case) and diabetes mellitus (DM) (1/38 case). There were no statistical difference in coexisting disease between the two groups [ Figure 1 ].
The concomitant medication received along with AMB for comorbid conditions were anti-tubercular therapy (ATT), pyridoxine, cotrimoxazole, clotrimazole, sulphadoxine+ pyrimethamine, enalapril and insulin. Antiretroviral therapy was noted in 24 patients, 14 in the low dose group and 10 in the high dose group.
Among the 26 patients from low dose group, 3three patients were empirically treated CM for 14 days. Two patients were discharged against medical advice on the fourth and ninth day of AMB treatment. Among the 21 patients, 15 patients completed treatment. Of these 15 patients, 14 patients were cured completely but one patient remained microbiologically positive for C.neoforman after 14 days of therapy. Six patients expired between the fi rst and the ninth day, after initiation of amphotericin B treatment (23.07% patients). Among the 15 patients from low dose group, relapse was seen in four patients, of these two patients expired. The overall mortality of 30.76% (8/26 cases) was seen in the low dose group.
Twelve patients were categorized under high dose group. Of these, three were discharged against medical advice. Among the nine patients who completed treatment, two who showed clinical improvement remained microbiologically positive by India ink preparation for C.neoforman after 14 days of therapy. Seven patients showed complete cure. No patients were treated empirically. Neither relapse or nor mortality was reported in group B. Table 3 shows comparison of effi cacy between the two groups.
The commonest adverse effects were fever, chills with rigor (17/38 cases), vomiting (14/38 cases), hypokalemia (19/38 cases), thrombophlebitis (10/38 cases), increased serum creatinine (8/38 cases), seizures (6/38 cases), hyponatremia (3/38 cases), facial puffi ness (4/38 cases). Comparisons between the two groups [ Table 4 ] showed that hypokalemia and facial puffi ness were more in high dose group which was statistically signifi cant (P=0.04 and P=0.01 respectively). All other adverse effects were comparable between the two groups.
Discussion
Cryptococcal meningitis is increasing because of rising population of immunocompromized individuals particularly those with AIDS. [5] Fungal infections are a major cause of morbidity and mortality in HIV. Untreated cryptococcal meningitis is fatal.
The recommended initial treatment for acute disease is amphotericin B for two weeks duration. Main limitation in the use of AMB is its toxicity. Acute infusion-related reactions fever, chills with rigors and hypokalemia. In our study also it has been seen that infusion related side effects like fever, chills with rigor, vomiting are common. Pre-medication before receiving AMB can help to prevent/ reduce some side effects during infusion. [12] In our study, pretreatment with antipyretics, antihistaminics and corticosteroids has helped to lessen these effects.
AMB can also cause signifi cant electrolyte abnormalities (hypokalemia and hypomagnesaemia). These effects occur in the majority of patients within the fi rst week of therapy. Electrolytes should be monitored daily and replaced as needed. [13] Hypokalemia and hyponatremia are seen in the present study. This electrolyte imbalance is corrected by giving appropriate electrolytes and fl uids. Patients treated with AMB should be monitored for dose dependent nephrotoxicity. In our study there was a increased serum creatinine observed in both the groups. But facial puffi ness was predominantly observed in high dose therapy group (P=0.01), which may be indicative of a dose-dependent nephrotoxicity.
Diagnosis of invasive fungal infections early, reliably and defi nitively continues to be a major challenge to practitioners. As a result, empiric therapy is generally initiated in response to a persistent fever in a vulnerable patient. [14] The same trend was seen in the present study also. Although CSF did not shown positive results for cryptococcal meningitis, three out of 38 patients (7.89% cases) who presented with intense headache, signs of meningitis with low CD 4 cell count and marginally elevated protein where treated empirically.
A potential strategy for reducing AMB associated toxicity is the use of liposomal and other lipid-based formulations containing AMB. [15, 16] These formulations have shown a reduced toxicity and have permitted the use of higher doses of AMB, which potentially could lead to an increased therapeutic index. [17] These so called liposomal formulations of AMB are very expensive, thus limiting their use. Drug acquisition costs for all these products are much higher than for conventional AMB.
Treatment with a low daily dose of AMB in AIDS patients with cryptococcal meningitis has been associated with low effi cacy and high mortality. [18] In the present study, high mortality was seen in the low dose therapy group (30.76%) when compared to the high dose therapy group.
The standard recommended dose for AMB for the treatment of cryptococcal meningitis is 0.7 to 1.0 mg/kg/ day. [19] In view of the cost of therapy and fear of adverse events clinicians were using low dose for patients who could not afford high dose and who had poor nutritional status.
Results of our study clearly showed that low dose therapy was associated with a signifi cant high mortality (8 versus 0 with a P value <0.02) and higher relapse rate although this was not statistically signifi cant because of the small number in the high dose group. Occurrence of hypokalemia was signifi cantly high in high dose group however this was easily correctable. Puffi ness of face is signifi cantly high in patients on high dose as compared to low dose indicating sub-clinical renal dysfunction.
All the side effects were easily treated and none of them life-threatening. Hence fear of side effect should not be a cause of concern for the physicians to prescribe high dose of AMB for CM.
Use of potent antiretroviral therapies results in a decrease in the incidence of opportunistic infections associated with AIDS. [20] Highly active anti-retroviral therapy has changed the face of HIV/AIDS by leading to a dramatic decrease in HIV related morbidity and mortality among those with accesses to therapy. [21] In this study, more number of patients in the high dose group received anti-retroviral therapy when compared to low dose group (P=0.08). Obviously the outcome of therapy resulting in higher effi cacy for the high dose group.
Conclusion
High dose of amphotericin B therapy is more effi cacious. However hypokalemia and clinical features of nephrotoxicity was higher with patients on high dose therapy, which can be managed by proper monitoring. ) .
